Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Judy Dering
Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
HER-2 Overexpression Differentially Alters Transforming Growth Factor-Β Responses in Luminal Versus Mesenchymal Human Breast Cancer Cells
Breast Cancer Research
Cancer Research
Oncology
Related publications
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Frontiers in Oncology
Cancer Research
Oncology
Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Investigational New Drugs
Oncology
Pharmacology
BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer
PLoS ONE
Multidisciplinary
Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3
European Journal of Cancer
Cancer Research
Oncology
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
Pcn180 - Pharmacoeconomic Assessment of Fulvestrant Versus Dd (Doxorubicin, Docetaxel) Therapy in Postmenopausal Women With Metastatic Er (+) Her2 (-) Breast Cancer in Ukraine
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation
Medicine
Pharmacology
